ExodusPoint Capital Management’s Co-Diagnostics CODX Stock Holding History

ExodusPoint Capital Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-443	Closed	-$82K	–	2006
2022 Q1	$82K	Buy	+443	New	+$91.7K	﹤0.01%	2024
2021 Q3	–	Sell	-2,158	Closed	-$534K	–	2185
2021 Q2	$534K	Buy	+2,158	New	+$555K	0.01%	1347
2021 Q1	–	Sell	-690	Closed	-$192K	–	2166
2020 Q4	$192K	Buy	690 +277	+67%	+$103K	﹤0.01%	1743
2020 Q3	$168K	Buy	+413	New	+$212K	﹤0.01%	1520
2020 Q2	–	Sell	-390	Closed	-$89K	–	1802
2020 Q1	$89K	Buy	+390	New	+$67.6K	﹤0.01%	902

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's CODX Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 443 shares — an estimated $82K sold.

ExodusPoint Capital Management first reported a position in CODX in Q1 2020 and held it in 5 quarters. The position peaked at $534K in Q2 2021. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

ExodusPoint Capital Management reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 443 Co-Diagnostics shares in Q2 2022, an estimated $82K.
ExodusPoint Capital Management first reported a position in Co-Diagnostics in Q1 2020 and held it in 5 quarters.
ExodusPoint Capital Management's Co-Diagnostics position peaked at $534K in Q2 2021.
69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.